Orion Oyj operates within the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Orion Oyj with three other pharmaceutical manufacturers in Europe: Indivior Plc of the United Kingdom (2018 sales of £755.36 million [US$980.98 million] of which 100% was Buprenorphine Based Drugs), Swedish Orphan Biovitrum AB (publ) of Sweden (9.14 billion Swedish Kronor [US$981.97 million] of which 100% was Sales of Pharmaceuticals), and Alkermes Plc which is based in Ireland (928.72 million Euro [US$1.05 billion] of which 100% was Pharmaceuticals).

Sales Analysis. During the year ended December of 2018, sales at Orion Oyj were 977.50 million Euro (US$1.10 billion). This is a decrease of 9.9% versus 2017, when the company's sales were 1.08 billion Euro. The sales level in 2018 was fairly close to the level five years ago: in 2013, Orion Oyj had sales of 1.01 billion Euro.